Top Markets
#1 Pleasing Gold Pleasing Gold +1,546.27%
#2 PulseChain PulseChain +55.72%
#3 Ontology Gas Ontology Gas +36.94%
#4 DogBull DogBull +36.89%
#5 BOOK OF MEME BOOK OF MEME +30.55%
#6 Neiro Neiro +21.85%
#7 Collect on Fanable Collect on Fanable +21.43%
#8 Nockchain Nockchain +19.56%
#9 Pump.fun Pump.fun +19.14%
#10 Unit Pump Unit Pump +19.14%
Coin of the day
Pleasing Gold Pleasing Gold
Settings
Language
ENGLISH
Currency
USD
Theme
PharmAust Limited PharmAust Limited

PharmAust Limited

PAA
Rank in Stocks #26700
Operating internationally, including in Switzerland, Australia, Sweden, and the... Operating internationally, including in Switzerland, Australia, Sweden, and the United States, PharmAust Limited specializes in developing targeted cancer treatments for both human and animal applications. The company also cultivates intellectual property in drug discovery, addressing a range of cancers and neurological conditions. Its primary therapeutic candidate is Monepantel (MPL), a small molecule compound currently undergoing Phase II clinical trials for cancer treatment. Beyond its drug development pipeline, PharmAust provides synthetic and medicinal chemistry products and expert services to the global drug discovery and pharmaceutical sectors. The firm also holds a research agreement with the Walter and Eliza Hall Institute, investigating in vitro the effects of MPL on human T-lymphotrophic virus-1 (HTLV-1) infections. Established in 2000, PharmAust Limited is headquartered in Bentley, Australia.
Share Price
$0.12164306
Last synced: 2024-11-11
Market Cap
$38.53M
Change (1 day)
-4.14%
Change (1 year)
0.00%
Country
AU
Trade PharmAust Limited (PAA)

Category

Healthcare
Revenue for PharmAust Limited (PAA)
Revenue in Jun 2024 TTM: $572.45K
According to PharmAust Limited latest financial reports the company's current revenue (TTM) is $572.45K. In 2023 the company made a revenue of $1.88M a decrease compared to the revenue in the year 2022 that was $2.33M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for PharmAust Limited from 2001 to 2026
Revenue at the end of each year
Year Revenue Change
2026 (TTM) $572.45K 0.00%
2024 0.00 -100.00%
2023 $1.88M -19.32%
2022 $2.33M 45.33%
2021 $1.60M -27.22%
2020 $2.21M -27.76%
2019 $3.05M 26.47%
2018 $2.41M -5.23%
2017 $2.55M 25.80%
2016 $2.02M 10.90%
2015 $1.83M -0.20%
2014 $1.83M 17.05%
2013 $1.56M -5.48%
2012 $1.65M -0.67%
2011 $1.66M 19.79%
2010 $1.39M -2.17%
2009 $1.42M -47.01%
2008 $2.68M -55.73%
2007 $6.05M 33.53%
2006 $4.53M 85.63%
2005 $2.44M 1,047.74%
2004 $212.83K 366.98%
2003 $45.58K -88.07%
2002 $381.98K 0.00%
2001 0.00 0.00%
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B 2,205,224.96%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B 1,051,752.00%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B 2,741,683.32%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B 389,106.85%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH